France sets up agency for medical bioethics
By Agence France-Presse,
Agence France-Presse
| 05. 10. 2005
PARIS (AFP) - France inaugurated a specialised agency for approving research on embryonic stem cells and vetting organ donations and other bioethics issues.
The creation of the Biomedicine Agency follows up on a new law, approved by parliament last August and due to take effect this month.
Under it, French health scientists will be permitted to draw on the country's stock of tens of thousands of surplus embryos in order to create lines of stem cells.
These embryos were created years ago through in-vitro fertilisation (IVF) to help infertile couples, but are no longer wanted and remain in freezers in fertility clinics.
Stem cells are immature cells that are like blank slates. In this early state, they have yet to differentiate into the specific cells that make up the body's tissues.
The goal among scientists is to harvest these cells and coax them into growing into fresh, replacement tissue which can then be transplanted into the body to reverse brain, nerve, muscle and organ damage.
The most versatile stem cells come from embryos that are a few days old. These...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...